F0806
Factor IX human
aqueous glycerol solution, ≥145 units/mg protein
Sinonimo/i:
Christmas factor, Plasma thromboplastin component
Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
100 μG
CHF 313.00
Informazioni su questo articolo
Form:
aqueous glycerol solution
Biological source:
human
Mol wt:
55 kDa
Vai a
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti1 of 4
Questo articolo | |||
|---|---|---|---|
| technique(s) ligand binding assay: suitable | technique(s) - | technique(s) - | technique(s) ligand binding assay: suitable |
| biological source human | biological source - | biological source - | biological source human |
| mol wt 55 kDa | mol wt - | mol wt - | mol wt - |
| form aqueous glycerol solution | form liquid | form liquid | form aqueous glycerol solution |
| shipped in wet ice | shipped in wet ice | shipped in wet ice | shipped in wet ice |
| specific activity ≥145 units/mg protein | specific activity ≥20 units/mg protein | specific activity ≥85 units/mg protein (clotting assay) | specific activity ≥25 units/mg protein |
General description
Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.
Application
Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).
Physical form
Aqueous solution containing 50% (v/v) glycerol
Other Notes
One unit is equivalent to the Factor IX activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
View this factors role in the Coagulation Cascade
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Classe di stoccaggio
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Uri Martinowitz et al.
Thrombosis research, 131 Suppl 2, S11-S14 (2013-03-30)
Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) is a novel recombinant albumin fusion protein designed to extend the half-life of recombinant factor IX (rFIX), which is used in the management of hemophilia B. Clinical evaluation of rIX-FP
Cassandra L Pegg et al.
Glycoconjugate journal, 37(4), 471-483 (2020-05-08)
Human Factor IX is a highly post-translationally modified protein that is an important clotting factor in the blood coagulation cascade. Functional deficiencies in Factor IX result in the bleeding disorder haemophilia B, which is treated with plasma-derived or recombinant Factor
Sweta Gupta et al.
British journal of haematology, 161(3), 424-433 (2013-02-26)
This study prospectively compared the effect of secondary prophylaxis to episodic treatment on target joint (TJ) range of motion (ROM), number of joint haemorrhages and new TJ development in patients with moderate or severe haemophilia. Two-hundred and eighty-six males, 17%
[Hemophilia].
Midori Shima
[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(2), 189-197 (2013-03-09)
Mariko Yamamoto et al.
[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(3), 300-304 (2013-05-17)
This report describes the successful management of neurosurgical procedures with continuous infusion of recombinant factor IX (rFIX). A 1-year-old boy with severe hemophilia B was administered prophylactic therapy with rFIX after intracranial bleeding. We found the enlargement of an arachnoid
Contenuto correlato
Instructions
Active Filters
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica